This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mazzoni, A. Articles by Canevari, S. Search for Related Content PubMed PubMed Citation Articles by Mazzoni, A. Articles by Canevari, S.

CD3-CD28 Costimulation as a Means to Avoiding T Cell Preactivation in Bispecific Monoclonal Antibody-based Treatment of Ovarian Carcinoma¹

Division of Experimental Oncology E, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy [A. M., D. M., M. I. C., S. C.], and Labor für Rationale Immuntherapie Medizinische Klinik III der Universität München and GSF, Institut für Klinische Hämatologie, 81377 Munich, Germany [G. J., H. W.]

One of the major limitations to the immunotherapy of ovarian carcinoma based on the use of anti-CD3/antitumor bispecific monoclonal antibodies (bi-mAb) is the need for preactivation of effector cells ex vivo, because cross-linking of the T cell receptor-CD3 complex per se may lead to T-cell unresponsiveness or even apoptosis. The bi-mAb OC/TR, which recognizes the folate-binding protein (FBP) overexpressed in 90% of ovarian carcinomas and the CD3 molecule on T cells, has demonstrated efficacy in a clinical setting. Here we investigated the possibility of delivering accessory signals to OC/TR-retargeted peripheral blood mononuclear cells (PBMCs) via an anti-CD28 mAb or an anti-FBP/anti-CD28 bi-mAb.

Coculture of resting PBMCs from healthy donors with OC/TR, anti-FBP/anti-CD28 bi-mAb, and FBP⁺ tumor cell lines resulted in a highly activated phenotype of effector cells and in a dramatic in vitro growth inhibition of the target cells without an increase in OC/TR-redirected lysis. Whereas both the CD4 and CD8 T cell subsets were involved in the growth inhibition, only the CD8 subpopulation accounted for the cytotoxic activity. The in vitro tumor growth inhibition was mediated mainly by soluble factors, which were active on both FBP⁺ and FBP^- ("bystander effect") cell lines. Activation and antitumor activity were also observed, albeit to a lesser extent, using OC/TR and monospecific bivalent anti-CD28 mAb. In vitro analysis demonstrated that cross-linking between tumor and effector cells for at least 24 h was needed to achieve T-cell activation and development of antitumor activities. Thus, ex vivo CD3-CD28 costimulation on resting PBMCs might be of therapeutic utility for local treatment of minimal residual disease.

¹ This work was supported in part by Consiglio Nazionale delle Ricerche-Applicazioni Cliniche della Ricerca Oncologia, Associazione Italiana per la Ricerca sul Cancro/Federazione Italiana Ricerca Cancro, and Ministero della Sanità.

² Present address: Baxter Deutschland GmbH, Immunotherapy Division, Edisonstr. 3, 85716 Unterschleissheim, Germany.

³ To whom requests for reprints should be addressed. Phone: 39-2-2390565; Fax: 39-2-2362692.

Received 7/22/96. Accepted 9/30/96.

This article has been cited by other articles:

				K. Hasegawa, T. Nakamura, M. Harvey, Y. Ikeda, A. Oberg, M. Figini, S. Canevari, L. C. Hartmann, and K.-W. Peng The Use of a Tropism-Modified Measles Virus in Folate Receptor-Targeted Virotherapy of Ovarian Cancer. Clin. Cancer Res., October 15, 2006; 12(20): 6170 - 6178. [Abstract] [Full Text] [PDF]

				A. J. Stel, B.-J. Kroesen, S. Jacobs, H. Groen, L. F. M. H. de Leij, H. C. Kluin-Nelemans, and S. Withoff The Role of B Cell-Mediated T Cell Costimulation in the Efficacy of the T Cell Retargeting Bispecific Antibody BIS20x3 J. Immunol., November 15, 2004; 173(10): 6009 - 6016. [Abstract] [Full Text] [PDF]

				D. Mezzanzanica, E. Balladore, F. Turatti, E. Luison, P. Alberti, M. Bagnoli, M. Figini, A. Mazzoni, F. Raspagliesi, M. Oggionni, et al. CD95-Mediated Apoptosis Is Impaired at Receptor Level by Cellular FLICE-Inhibitory Protein (Long Form) in Wild-Type p53 Human Ovarian Carcinoma Clin. Cancer Res., August 1, 2004; 10(15): 5202 - 5214. [Abstract] [Full Text] [PDF]

				I. Renard, D. Mezzanzanica, S. Canevari, S. Ferrini, J. Boniver, P. Delvenne, and N. Jacobs Anti-CD3/Anti-Epidermal Growth Factor Receptor-Bispecific Antibody Retargeting of Lymphocytes against Human Neoplastic Keratinocytes in an Autologous Organotypic Culture Model Am. J. Pathol., January 1, 2002; 160(1): 113 - 122. [Abstract] [Full Text] [PDF]

				M. Wu, W. Gunning, and M. Ratnam Expression of Folate Receptor Type {{alpha}} in Relation to Cell Type, Malignancy, and Differentiation in Ovary, Uterus, and Cervix Cancer Epidemiol. Biomarkers Prev., September 1, 1999; 8(9): 775 - 782. [Abstract] [Full Text]

				P. Holliger, O. Manzke, M. Span, R. Hawkins, B. Fleischmann, L. Qinghua, J. Wolf, V. Diehl, O. Cochet, G. Winter, et al. Carcinoembryonic Antigen (CEA)-specific T-Cell Activation in Colon Carcinoma Induced by Anti-CD3Anti-CEA Bispecific Diabodies and B7Anti-CEA Bispecific Fusion Proteins Cancer Res., June 1, 1999; 59(12): 2909 - 2916. [Abstract] [Full Text] [PDF]

				G. Strau{beta}, B. Guckel, D. Wallwiener, and G. Moldenhauer Without Prior Stimulation, Tumor-associated Lymphocytes from Malignant Effusions Lyse Autologous Tumor Cells in the Presence of Bispecific Antibody HEA125xOKT3 Clin. Cancer Res., January 1, 1999; 5(1): 171 - 180. [Abstract] [Full Text] [PDF]

				H. M. Finney, A. D. G. Lawson, C. R. Bebbington, and A. N. C. Weir Chimeric Receptors Providing Both Primary and Costimulatory Signaling in T Cells from a Single Gene Product J. Immunol., September 15, 1998; 161(6): 2791 - 2797. [Abstract] [Full Text] [PDF]